Heart Failure

Less than 2 weeks after the release of their SELECT reaction podcast, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down for a special edition episode of Diabetes Dialogue to discuss STEP-HFpEF data and the implications for semaglutide 2.4 mg.

With BridgeBio Pharma Inc. expecting to complete a regulatory submission prior to the close of 2023, the 30-month results of ATTRibute-CM provide the most comprehensive overview yet of the benefit-risk profile for acoramidis in ATTR-CM.

Javed Butler, MD, discusses the overall results of the STEP-HFpEF trial, how he interprets the reduction in adjudicated heart failure events, and how the community's recent experience with SGLT2 inhibitors might inform uptake strategies for semaglutide 2.4 mg.

The largest trial to date, a meta-analysis, and new guideline recommendations have placed a spotlight on the role and benefit of iron supplementation in patients with heart failure and iron deficiency at ESC Congress 2023.

Citing more than half a dozen major trials in the 2 years since the release of their 2021 heart failure guidelines, the European Society of Cardiology has released a focused update to their heart failure guidance.

Results of the STEP-HFpEF trial suggest use of semaglutide 2.4 mg (Wegovy) was associated with improvements in physical symptoms and functional status relative to placebo therapy in adults with HFpEF and obesity.

Presented at ESC 2023, the accumulation of inactive time from childhood through young adulthood was related to heart damage, regardless of body weight and blood pressure.

A new analysis suggests improved self-recognition of myocardial infarction symptoms may reduce cardiogenic shock and death by prompting a rapid hospital visit.

A multi-center study in France found recreational drug use was independently associated with the occurrence of in-hospital outcomes.

In this episode of Don't Miss a Beat, hosts offer a breakdown of 3 trials of note from the upcoming ESC Congress 2023 and provide context around the recent announcement of topline results from the SELECT trial.

A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.

Last week, the FDA authorized marketing for Viz.AI’s Viz HCM, a standalone ECG analysis software to identify adult patients for further follow-up for hypertrophic cardiomyopathy.

The July 2023 cardiology month in review features a Class I recall from the FDA, the latest recommendation statement from the USPSTF, and an update on 3 agents in the pipeline.

Data from a phase 1, first-in-human trial of NI006 suggests the agent could have a potential role in the management of transthyretin amyloid cardiomyopathy.

Days with a combination of a heat wave and high fine particulate matter air pollution may double the risk of a fatal heart attack, says new research.

A new analysis suggests Black patients with NICM and an ICD had a high risk and burden of arrhythmia, with a lower survival rate, compared with White patients.

A new analysis from the American Heart Association found present-day heart failure risk was higher among Black adults who lived in areas historically impacted by redlining.

Experts in cardiology discuss the use of sacubitril/valsartan in patients with heart failure with preserved ejection fraction (HFpEF), highlighting the PARAGLIDE-HF study.

Robert J. Mentz, MD, and Javed Butler, MD, MPH, MBA, comment on the use of beta blockers and other agents in patients with heart failure preserved ejection fraction (HFpEF).

Physical activity concentrated within a 1- to 2-day span was associated with a similarly lower risk of cardiovascular outcomes to more evenly distributed activity.

Anuradha Lala-Trindade, MD, provides an overview of SGLT2 inhibitors for the management of heart failure, as well as their clinical trial data.

An expert cardiologist reviews the foundational pillars of quadruple-based, guideline therapies for heart failure, as well as the contraindications for these drugs.

An analysis of NHANES data is offering clinicians an overview of associations between hyperuricemia and gout with increased risk of mortality in patients with heart failure.

Robert J. Mentz, MD, reviews the current unmet needs for patients with heart failure, highlighting triple or quadruple therapy.

Javed Butler, MD, MPH, MBA, comments on implementing, continuing or cutting back on quadruple therapy after patient’s cardiac function has improved.

Anuradha Lala-Trindade, MD, comments on the prevalence of the various types of heart failure, as well as risk factors leading to the disorder.

Anuradha Lala-Trindade, MD, discusses the challenges in managing heart failure in the United States as well as the universal definition of heart failure and classification by left ventricle ejection fraction (EF).

Drs James Januzzi, Javed Butler, Robert J. Mentz, and Muthiah Vaduganathan share approaches to sequencing quadruple therapy in heart failure to the individual patient, as well as optimizing therapy early in the hospitalization stage.

Javed Butler, MD, MPH, MBA, discussesSGLT-2 inhibitors and their use in heart failure.

Experts in cardiology highlight the four pillars of guideline directed therapies in heart failure.